Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells

Bisphosphonates such as alendronate are antiosteoporotic drugs that inhibit the activity of bone-resorbing osteoclasts and secondarily promote osteoblastic function. Diabetes increases bone-matrix-associated advanced glycation end products (AGEs) that impair bone marrow progenitor cell (BMPC) osteog...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuguransky, Sara Rocío, Cortizo, Ana María, McCarthy, Antonio Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093246/
https://www.ncbi.nlm.nih.gov/pubmed/27840829
http://dx.doi.org/10.1155/2016/5891925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093246/
https://www.ncbi.nlm.nih.gov/pubmed/27840829
http://dx.doi.org/10.1155/2016/5891925

Ejemplares similares